Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT07224139
Active, not recruiting Observational

Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias

NCT07224139 · tracked via the Priya Life Science Australia tracker
Sponsor
Anne Murray
Phase
Observational
Started
2022-07-01
Last updated
2025-11-04

Condition(s) studied

Alzheimer DiseaseDementiaCognitive Dysfunction

Study summary

Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for personalized medicine and clinical trials.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: We will use de-identified data and biospecimens originally collected for a large binational NIA-funded ASPirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial and ongoing observational follow-up (U19 AG062682) for analysis. Exclusion Criteria: None

Primary outcome measure(s)

  • To prospectively measure plasma AT(N) biomarkers and to identify participant characteristics that are associated with these levels separately in women and men. — In a community population of 21,000 older persons without dementia, we will measure changes in these biomarkers over 7 to 10 years
    We hypothesize that: 1a. There will be sex differences in the cross-sectional biomarker levels, and in their trajectories over time. 1b. Chronic comorbidities and genetic risk factors (APOE ε4, polygenic risk score) will be associated with 'worse' AT(N) biomarker levels (reflecting worse ADRD pathology) at baseline and with a greater increase over time over time, and that these associations will differ between men and women.

Trial sites (5)

FacilityCityRegionStatus
Foundation for Atlanta Veterans Education and Research, Inc. Decatur Georgia
Hennepin Healthcare Research Institute Minneapolis Minnesota
Regents of the University of Minnesota - Advanced Research & Diagnostic Minneapolis Minnesota
Wake Forest University Winston-Salem North Carolina
Monash University Melbourne Victoria

More Anne Murray trials in Australia

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT) Active, not recruiting

Other trials for the same condition

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis Recruiting
TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease Recruiting
Small Steps Towards Improving Activity and Sleep Habits to Decrease the Risk of Dementia Active, not recruiting
Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT) Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07224139 on ClinicalTrials.gov ↗ ← All trials in Australia